The role of chelators in preventing biofilm formation and catheter-related bloodstream infections

Current Opinion in Infectious Diseases

Volumn 21, Issue 4, 2008, Pages 385-392

  Raad, Issam I ^a   Fang, Xiang ^a   Keutgen, Xavier M ^a   Jiang, Ying ^a   Sherertz, Robert ^b   Hachem, Ray ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial lock solution; Biofilm; Catheter related bloodstream infection; Chelator; Metal iron

Indexed keywords

CALCIUM ION; CHELATING AGENT; CITRATE TRISODIUM; CITRIC ACID; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; EDETIC ACID; ETHYLENEDIAMINE N,N' BIS(2 HYDROXYPHENYLACETIC ACID); GENTAMICIN; HEPARIN; IRON; LACTOFERRIN; MAGNESIUM ION; MINOCYCLINE; PENTETIC ACID; SUCCIMER; TAUROLIDINE; TRANSFERRIN; ANTIINFECTIVE AGENT;

BACTERIAL COLONIZATION; BACTERIUM ADHERENCE; BINDING AFFINITY; BIOFILM; BLOOD VESSEL CATHETERIZATION; CATHETER INFECTION; CHELATION; HUMAN; INFECTION PREVENTION; NONHUMAN; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; APPARATUS, EQUIPMENT AND SUPPLIES; BACTEREMIA; CATHETERIZATION; DRUG EFFECT; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL ADHESION; BIOFILMS; CATHETERIZATION; CHELATING AGENTS; CITRIC ACID; EDETIC ACID; EQUIPMENT AND SUPPLIES; HUMANS;

EID: 49049116192     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32830634d8     Document Type: Review

References (98)

1. Raad I, Luna M, Khalil S, et al. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994; 271:1014-1016.
2. Maki D, Cobb L, Garman J, et al. An attachable silver-impregnated cuff for prevention of infection with central venous catheters: a prospective randomized multicenter trial. Am J Med 1988; 85:307-314.
3. Pittet D, Tarara D, Wenzel R. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271:1598-1601.
4. Raad I. Intravascular-catheter-related infections. Lancet 1998; 351:893-898.
5. Tojo M, Yamashita N, Goldmann DA, et al. Isolation and characterization of a capsular polysaccharide adhesion from Staphylococcus epidermidis. J Infect Dis 1988; 157:713-722.
6. Sheth N, Franson T, Sohnle P. Influence of bacterial adherence to intravascular catheters on in-vitro antibiotic susceptibility. Lancet 1985; 2:1266-1268.
7. Falcieri E, Vaudaux P, Huggler E, et al. Role of bacterial exopolymers and host factors on adherence and phagocytosis of Staphylococcus aureus in foreign body infection. J Infect Dis 1987; 155:524-531.
8. Qin Z, Ou Y, Yang L, et al. Role of autolysin-mediated DNA release in biofilm formation of Staphylococcus epidermidis. Microbiology 2007; 153:2083-2092. This study suggested that extracellular DNA promotes biofilm formation of S. epidermidis.
9. Christensen G, Simpson W, Bisno A, et al. Adherence of slime producing strains of Staphylococcus epidermidis to smooth surfaces. Infect Immun 1982; 37:318-326.
10. Christensen G, Simpson W, Younger J, et al. Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. J Clin Microbiol 1985; 22:996-1006.
11. Montanaro L, Arciola C, Borsetti E, et al. A polymerase chain reaction (PCR) method for the identification of collagen adhesion gene (CNA) in Staphylococcus-induced prosthesis infections. New Microbiol 1998; 21:359-363.
12. McKenney D, Pouliot K, Wang Y, et al. Broadly protective vaccine for Staphylococcus aureus based on an in vitro-expressed antigen. Science 1999; 284:1523-1527.
13. Cramton S, Gerko C, Schnell N, et al. The intercellular adhesion (ica) hocus is present in Staphylococcus aureus and is required for biofilm formation. Infect Immun 1999; 67:5427-5433.
14. Arciola C, Montanaro L, Baldassarri L, et al. Slime production by staphylococci isolated from prosthesis- associated infections. New Microbiol 1999; 22:337-341.
15. Ammendolia M, Di Rosa R, Montanaro L, et al. Slime production and expression of the slime associated antigen by staphylococcal clinical isolated. J Clin Microbiol 1999; 37:3235-3238.
16. Stewart P, Costerton J. Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358:135-138.
17. Pfaller M, Messer S, Hollis R. Variations in DNA subtype, antifungal susceptibility, and slime production among clinical isolates of Candida parapsilosis. Diagn Microbiol Infect Dis 1995; 21:9-14.
18. Maki D. Infection caused by intravascular devices: pathogensis, strategies for prevention. London: Royal Society of Medicine Services; 1991.
19. Elting L, Bodey G. Septicemia due to Xanthomonas species and nonaeruginosa Pseudomons species: increasing incidence of catheter-related infections. Medicine (Baltimore) 1990; 69:296-306.
20. Seifert H, Strate A, Pulverer G. Vascular catheter related bloodstream infection due to Acinetobacter johnsonii (formerly Acinetobacter calcoaceticus var. Lwoffi): report of 13 cases. Clin Infect Dis 1993; 17:632-636.
21. Ambler M, Homans A, O'Shea P. An unusual central nervous system infection in a young immunocompromised host. Arch Pathol Lab Med 1986; 110:497-501.
22. Raad I, Hanna H, Boktour M, et al. Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 2004; 38:1119-1127.
23. Mermel L, Farr B, Sherertz R, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32:1249-1272.
24. O'Grady N, Alexander M, Dellinger E, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for disease control and prevention. MMWR Recomm Rep 2002; 51:1-29.
25. Raad I, Costerton W, Sabharwal U, et al. Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis 1993; 168:400-407.
26. Cowan C. Antibiotic lock technique. J Intraven Nurs 1990; 15:283-287.
27. Messing B, Peitra-Cohen S, Debur A, et al. Antibiotic-lock technique: a new approach to patients. J Parenter Enteral Nutr 1988; 12:185-189.
28. Douard M, Arlet G, Longuet P, et al. Diagnosis of venous access port-related infections. Clin Infect Dis 1999; 29:1197-1202.
29. Johnson D, Johnson F, Goldman S. Preliminary results treating persistent central venous catheter infections with the antibiotic lock technique in pediatric patients. Pediatr Infect Dis J 1994; 13:930-931.
30. Williams N, Carlson G, Scott N, et al. Incidence and management of catheter-related sepsis in patients receiving home parenteral nutrition. Br J Surg 1994; 81:392-394.
31. Benoit J, Carandang G, Sitrin M, et al. Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home. Clin Infect Dis 1995; 21:1286-1288.
32. Krzywda E, Andris D, Edminston C Jr, et al. Treatment of Hickman catheter sepsis using antibiotic lock technique. Infect Control Hosp Epidemiol 1995; 16:596-598.
33. Capdevila J, Segarra A, Planes A, et al. Successful treatment of haemodialysis catheter-related sepsis without catheter removal. Nephrol Dial Transplant 1993; 8:231-234.
34. Rao J, O'Meara A, Harvey T, et al. A new approach to the management of Broviac catheter infection. J Hosp Infect 1992; 22:109-116.
35. Evans R, Holmes C. Effect of vancomycin hydrochloride on Staphylococcus epidermidis biofilm associated with silicone elastomer. Antimicrob Agents Chemother 1987; 32:889-894.
36. Farber B, Kaplan M, Clogston A. Staphylococcus epidermidis biofilm associated with silicone elastomer. Antimicrob Agents Chemother 1990; 161: 37-40.
37. Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007; 51:1656-1660. This study investigated the efficacies of several antibiotics against MRSA embedded in biofilm and suggested that daptomycin, minocycline and tigecycyline should be considered for ALT, and rifampin should be considered for enhanced antistaphylococcal activity but not as a single agent.
38. Bailey E, Berry N, Cheesbrough. Antimicrobial lock therapy for catheter-related bacteraemia among patients on maintenance haemodialysis. J Antimicrob Chemother 2002; 50:615-617.
39. Guedon C, Nouvellon M, LaLaude O, et al. Efficacy of antibiotic-lock technique with teicoplanin in Staphylococcus epidermidis catheter-related sepsis during long-term parenteral nutrition. JPEN J Parenter Enteral Nutr 2002; 26:109-113.
40. Krishnasami Z, Carlton D, Bimbo L, et al. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney Int 2002; 61:1136-1142.
41. Longuet P, Doudard M, Arlet G, et al. Venous access port-related bacteremia in patients with acquired immunodeficiency syndrome or cancer: the reservoir as a diagnostic and therapeutic tool. Clin Infect Dis 2001; 32: 1776-1783.
42. Roy B, Datta A. A calmodulin inhibitor blocks morphogenesis in Candida albicans. FEMS Microbiol Lett 1987; 41:327-329.
43. Sarkisova S, Patrauchan M, Berglund D, et al. Calcium-induced virulence factors associated with the extracellular matrix of mucoid Pseudomonas aeruginosa biofilms. J Bacteriol 2005; 187:4327-4337.
44. Banin E, Brady K, Greenberg E. Chelator-induced dispersal and killing of Pseudomonas aeruginosa cells in a biofilm. Appl Environ Microbiol 2006; 72:2064-2069.
45. Dunne W, Burd E. The effects of magnesium, calcium, EDTA, and pH on the in vitro adhesion of Staphylococcus epidermidis to plastic. Microbiol Immunol 1992; 36:1019-1027.
46. Özerdem Akpolat N, Elci S, Atmaca S, et al. The effects of magnesium, calcium and EDTA on slime production by Staphylococcus epidermidis strains. Folia Microbiol 2003; 48:649-653.
47. Brubaker R. Mechanisms of bacterial virulence. Annu Rev Microbiol 1985; 39:21-50.
48. Ratledge C, Dover L. Iron metabolism in pathogenic bacteria. Annu Rev Microbiol 2000; 54:881-941.
49. Weinberg E. Suppression of bacterial biofilm formation by iron limitation. Med Hypotheses 2004; 63:863-865.
50. Banin E, Vasil M, Greenberg E. Iron and Pseudomonas aeruginosa biofilm formation. Proc Natl Acad Sci U S A 2005; 102:11076-11081.
51. Rhodes E, Shoemaker C, Menke SM, et al. Evaluation of different iron sources and their influence in biofilm formation by the dental pathogen Actinobacillus actinomycetemcomitans. J Med Microbiol 2007; 56:119-128. This study investigated in more detail the ability of A. actinomycetemcomitans smooth and rough isolates to interact with and use different compounds as iron sources, as well as the effects of these compounds on cell attachment and biofilm formation on plastic surfaces.
52. Muthukumar G, Nickerson K. Ca(II)-calmodulin regulation of fungal dimorphism in Ceratocystis ulmi. J Bacteriol 1984; 159:390-392.
53. Muthukumar G, Nickerson K. Ca(II)-calmodulin regulation of morphological commitment in Ceratocystis ulmi. FEMS Microbiol Lett 1985; 27:199-202.
54. Alsina A, Rodriguez-Del Valle N. Effects of divalent cations and functionally related substances on the yeast to mycelial transition in Sporothrix schenckii. Sabouraudia 1984; 22:1-5.
55. Mehall J, Saltzman D, Jackson R, et al. Fibrin sheath enhances central venous catheter infection. Crit Care Med 2002; 30:908-912.
56. Donlan R. Biofilms: microbial life on surfaces. Emerg Infect Dis 2002; 8:881-890.
57. Raad I, Chatzinikolaou I, Chaiban G, et al. In vitro and ex vivo activities of minocycline and EDTA against microorganisms embedded in biofilm on catheter surfaces. Antimicrob Agents Chemother 2003; 47:3580-3585.
58. Percival S, Kite P, Eastwood K, et al. Tetrasodium EDTA as a novel central venous catheter lock solution against biofilm. Infect Control Hosp Epidemiol 2005; 26:515-519.
59. Raad I, Hachem R, Tcholakian R, et al. Efficacy of minocycline and EDTA lock solution in preventing catheter-related bacteremia, septic phlebitis, and endocarditis in rabbits. Antimicrob Agents Chemother 2002; 46:327-332.
60. Shah C, Mittelman M, Costerton J, et al. Antimicrobial activity of a novel catheter lock solution. Antimicrob Agents Chemother 2002; 46:1674-1679.
61. Gil M, Casanoa M, Martinez J. Changes in the cell wall glycoprotein composition of Candida albicans associated to the inhibition of germ tube formation by EDTA. Arch Microbiol 1994; 161:489-494.
62. Root J, McIntyre O, Jacobs N, et al. Inhibitory effect of disodium EDTA upon the growth of Staphylococcus epidermidis in vitro: relation to infection prophylaxis of Hickman catheters. Antimicrob Agents Chemother 1988; 32:1627-1631.
63. Bergan T, Klaveness J, Aasen A. Chelating agents. Chemotherapy 2001; 47:10-14.
64. Vineeta N, Singh V, Makkar S. Anti microbial activity of dimercaptosuccinic acid (DMSA): a new chelating agent. J Indian Soc Pedod Prev Dent 2001; 19:160-163.
65. Chen X, Stewart P. Biofilm removal caused by chemical treatments. Water Res 2000; 34:4229-4233.
66. Rose R. The role of calcium in oral streptococcal aggregation and the implications for biofilm formation and retention. Biochim Biophys Acta 2000; 1475: 76-82.
67. Shanks R, Sargent J, Martinez R, et al. Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol Dial Transplant 2006; 21:2247-2255.
68. Sherertz R, Boger M, Collins C, et al. Comparative in vitro efficacies of various catheter lock solutions. Antimicrob Agents Chemother 2006; 50:101-105.
69. Raad I, Hanna H, Dvorak T, et al. Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percentage ethanol, rapidly eradicates organisms embedded in biofilm. Antimicrob Agents Chemother 2007; 51:78-83. This study concluded that M-EDTA in 25% ethanol is highly effective at rapidly eradicating S. aureus and C. parapsilosis embedded in biofilm adhering to catheter segments.
70. Allon M. Prophylaxis against dialysis catheter-related bacteremia with a novel antimicrobial lock solution. Clin Infect Dis 2003; 36:1539-1544.
71. Betjes M, van Agteren M. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant 2004; 19:1546-1551.
72. Weijmer M, Debets-Ossenkopp Y, Van De Vondervoort F, et al. Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Nephrol Dial Transplant 2002; 17:2189-2195.
73. Weijmer M, van den Dorpel M, Van de Ven PJ, et al. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol 2005; 16:2769-2777.
74. Guha A, Choudhury A, Unni B, et al. Effect of outer-membrane permeabilizers on the activity of antibiotics and plant extracts against Pseudomonas aeruginosa. Folia Microbiol (Praha) 2002; 47:379-384.
75. Ardehali R, Shi L, Janatova J, et al. The effect of apo-transferrin on bacterial adhesion to biomaterials. Artif Organs 2002; 26:512-520.
76. Singh P, Parsek M, Greenberg E, et al. A component of innate immunity prevents bacterial biofilm development. Nature 2002; 417:552-555.
77. Arakawa Y, Saito T, Saito H, et al. Ethylene glycol bis (beta-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA) inhibits the growth of Escherichia coli at alkaline pH. J Gen Appl Microbiol 2000; 46:127-131.
78. van Asbeck B, Marcelis J, Marx J, et al. Inhibition of bacterial multiplication by the iron chelator deferoxamine: potentiating effect of ascorbic acid. Eur J Clin Microbiol 1983; 2:426-431.
79. Zhang H, Tang J, Meng X, et al. Inhibition of bacterial adherence on the surface of stents and bacterial growth in bile by bismuth dimercaprol. Dig Dis Sci 2005; 50:1046-1051.
80. Bergan T, Klaveness J, Aasen A. Chelating agents. Chemotherapy 2000; 47: 10-14.
81. Ibrahim A, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007; 117: 2649-2657. This study sought to define the potential efficacy of deferasirox iron chelation therapy against experimental mucormycosis in vitro and in vivo and demonstrated that deferasirox is a highly effective treatment for mucormycisis.
82. Ibrahim A, Edwards J, Fu Y, et al. Deferiprone iron chelator as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 2006; 58:1070-1073.
83. Helander I, Mattila-Sandholm T. Permeability barrier of the gram-negative bacterial outer membrane with special reference to nisin. Int J Food Microbiol 2000; 60:153-161.
84. Hanna H, Raad I, Darouiche R. New approaches for prevention of intravascular catheter-related infections. Infect Med 2001; 18:38-48.
85. Bleyer A, Mason L, Russell G, et al. A randomized, controlled trial of a new vascular catheter flush solution (minocycline-EDTA) in temporary hemodialysis access. Infect Control Hosp Epidemiol 2005; 26:511-514.
86. Chatzinikolaou I, Zipf T, Hanna H, et al. Minocycline-EDTA lock solution for the prevention of implantable port infections in children with cancer. Clin Infect Dis 2003; 36:116-119.
87. McGovern P, Compher C, Evans-Stoner N, et al. Minocycline-disodium EDTA lock solution in a long-term parenteral nutrition population [abstract]. In: The 16th Annual Scientific Meeting of the Society for Healthcare and Epidemiology of America; 18-21 March 2006; Chicago, Illinois.
88. Raad I, Buzaid L, Rhyne J, et al. Minocycline and ethylenediaminetetraacetate for the prevention of recurrent vascular catheter infections. Clin Infect Dis 1997; 25:149-151.
89. Dogra G, Herson H, Hutchison B, et al. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study. J Am Soc Nephrol 2002; 13:2133-2139.
90. Dannenberg C, Bierbach U, Rothe A, et al. Ethanol-lock technique in the treatment of bloodstream infections in pediatric oncology patients with Broviac catheters. J Pediatr Hematol Oncol 2003; 25:616-621.
91. Shanks R, Donegan N, Grabber M, et al. Heparin stimulates Staphylococcus aureus biofilm formation. Infect Immun 2005; 73:4596-4606.
92. Chandra J, Mukherjee P, Ghannoum M. Optimization of antibiofilm lock solution for activity against fungal and bacterial biofilms [abstract]. In: The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17-20 September 2007; Chicago, Illinois.
93. Chandra J, Mukherjee P, Ghannoum M. B-Lock is superior to citrate-based lock therapy in prevention and treatment of bacterial and fungal biofilms [abstract]. In: The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17-20 September 2007; Chicago, Illinois.
94. Bestul M, Vandenbussche H. Antibiotic lock technique: review of the literature. Pharmacotherapy 2005; 25:211-227.
95. Capdevila J, Gavaldà J, Fortea J, et al. Lack of antimicrobial activity of sodium heparin for treating experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock technique. Clin Microbiol Infect 2001; 7:206-212.
96. Arepally G, Cines D. Heparin-induced thrombocytopenia and thrombosis. Clin Rev Allergy Immunol 1998; 16:237-247.
97. Fallgren C, Utt M, Ljungh A. Isolation and characterisation of a 17-kDa staphylococcal heparin-binding protein with broad specificity. J Med Microbiol 2001; 50:547-557.
98. Liang O, Ascencio F, Fransson L, et al. Binding of heparan sulfate to Staphylococcus aureus. Infect Immun 1992; 60:899-906.